NCT05686629View on ClinicalTrials.gov

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

March 31, 2025

Conditions

Novel COVID-19-Infected Pneumonia

Interventions

DRUG

Jaktinib hydrochloride tablets

2 doses per day, each containing two 50mg Jaktinib or placebo tablets

Trial Locations (1)

610042

West China Hospital Sichuan University, Chengdu

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT05686629 - An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia | Biotech Hunter | Biotech Hunter